Airway Therapeutics Completes Dose Escalation in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia
Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, announced today it successfully finished the dose escalation portion of its Phase 1b trial of zelpultide alfa for preventive use in very preterm infants at risk for bronchopulmonary dysplasia (BPD). Airway began recruiting patients on March 28, 2023 for daily treatment up to 7 days at the highest dose of zelpultide alfa (rhSP-D) following a Data Safety Monitoring Committee (DSMC) report of no safety concerns.
The Phase 1b trial is being conducted in the U.S. and Spain. Airway has established a subsidiary, Airway Spain SL, to lead the Phase 1b trial and subsequent clinical trials across the E.U.
“This is a significant milestone in our efforts to protect these infants from suffering severe BPD. The very favorable safety profile is particularly important in these extremely vulnerable preterm neonates,” said Airway CEO and Chief Medical Officer Marc Salzberg, M.D.
“The DSMC confirmed the excellent safety profile of zelpultide alfa following completion of the third cohort of infants who received the highest dose. This dose is being used in a fourth and final cohort which now also includes infants born at 23 - 24 weeks, the earliest gestational age in our study.”
As many as 2.5 million very preterm infants globally are at risk of developing BPD from lung damage caused by mechanical ventilation and oxygen support. Babies who develop BPD can suffer lifelong complications such as asthma and pneumonia as well as growth and developmental problems.
Zelpultide alfa is a recombinant version of the endogenous human SP-D, a protein essential to the lung’s immune defense in reducing inflammation and infection while modulating immune responses. The biologic is administered intratracheally during mechanical ventilation.
The Phase 1b trial is a randomized, blinded, air-sham controlled study to establish the safety and tolerability of zelpultide alfa. Interim analysis of the data is expected in early Q2 2023. The FDA and European Medicines Agency have granted orphan drug status to zelpultide alfa.
About Airway Therapeutics
Airway Therapeutics is a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, beginning with the most vulnerable populations. The company is advancing zelpultide alfa, a novel recombinant human protein hSP-D that reduces inflammation and infection in the body while modulating the immune response. Zelpultide alfa is Airway’s first candidate in development for prevention of BPD in very preterm infants and for treatment of COVID/CAP in seriously ill mechanically ventilated patients.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230411005273/en/
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace Announces New Management Structure1.6.2023 08:00:00 EEST | Press release
Axelspace Corporation (Head Office: Chuo-ku, Tokyo; CEO: Yuya Nakamura), a pioneer in microsatellites, announces its new management structure as of June 1, 2023. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230531006007/en/ New Management Team Members: Front Row, Left to Right: Atsushi Yasuoka (Head of AxelLiner Business Division), Yuya Nakamura (CEO) , Daigo Orihara (CFO), Tatsuhiko Fukasawa (Head of AxelGlobe Business Division). Back Row, Left to Right: Yusuke Nakanishi (CSSO), Ryuichi Kokubo (Co-CTO/Information Technology), Takashi Eishima (Co-CTO/Aerospace Engineering), Makiko Hamada (CHRO), Sasaki (CISO), Yoshihiro Ota (CSO) (Photo: Business Wire) Axelspace announcement URL https://www.axelspace.com/news/20230601/ Background of Transition to New Management Structure Since our establishment in 2008 by a team of three members, our company has built a solid reputation by engaging in the development, manufacturing, and op
Preventing the Effects of Climate Change: EliTerra®, a Technological Platform Dedicated to Biosolutions That Reduce the Water Needs of Field Crops1.6.2023 06:06:00 EEST | Press release
Elicit Plant announces the acceleration of its scientific developments and its product roadmap by presenting the one and only technological platform that offers biosolutions to help prevent climatic risks for field crops by reducing their water consumption by up to 20%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230530005298/en/ @elicitplant On the occasion of its participation in the ChangeNOW Summit, the event for solutions for the planet that takes place from May 25 to 27, 2023 in Paris, Elicit Plant unveils EliTerra®, its technological platform and associated products that allow crops to adapt to climate change, particularly to drought. This is a world first that will boost the marketing of new Elicit Plant BioSolutions with a favorable environmental profile, following on from the success of its first product, BEST-a, which enables corn to consume up to 20% less water. "This type of solution is particularly expected
IFF Completed Divestiture of Savory Solutions Business31.5.2023 23:15:00 EEST | Press release
IFF (NYSE:IFF) today announced that it has successfully completed the previously announced divestiture of its Savory Solutions business unit to PAI Partners (PAI), a leading global private equity firm with a strong focus on the food and consumer industry. Under PAI ownership, Savory Solutions Group has been rebranded to NovaTaste, a global leader in taste innovation with headquarters in Salzburg, Austria. “The sale of IFF’s Savory Solutions Group represents our continued efforts to optimize our portfolio as we focus on core businesses and strengthen our capital structure,” said Frank Clyburn, IFF CEO. “We remain steadfast in our commitment to further pursue portfolio optimization opportunities as we drive toward our deleverage target by the end of 2024. We’re grateful to our Savory Solutions colleagues, who have demonstrated their commitment to innovation, service and quality. We wish them the best in their new journey.” Cautionary Statement under the Private Securities Litigation Refo
UAE Pledges Additional $2.7bn in Industry Offtake Agreements, Invites Global Investors to Leverage Incentives31.5.2023 21:13:00 EEST | Press release
His Excellency Dr. Sultan Al Jaber, Minister of Industry and Advanced Technology, today announced $2.7 billion in offtake agreements for the UAE’s industrial sector in a move to boost local manufacturing, strengthen supply chains and attract international investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230531005894/en/ His Excellency Dr Sultan Al Jaber UAE Minister of Industry and Advanced Technology (Photo: AETOSWire) Addressing the second Make it in the Emirates Forum, HE Dr. Al Jaber said the new set of procurement opportunities would build on the previous forum’s offtake agreements. “One of the key achievements of last year’s forum was several leading national companies announcing their intention to invest $29.9 billion over the next decade to purchase 300 products from local manufacturers,” HE Dr. Al Jaber said. “I am pleased to share with you that in the first year alone, 28 percent of these offtake agreement
Carbios Will Receive Grants Totaling €54 Million From French State via France 2030 and Grand-Est Region1 to Finance Construction of World's First PET Biorecycling Plant and Accelerate R&D Activities31.5.2023 19:30:00 EEST | Press release
Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230531005830/en/ Carbios will receive grants totaling €54 million from French State via France 2030 and Grand-Est Region to finance construction of world's first PET biorecycling plant and accelerate R&D activities (Photo: Carbios) Carbios (Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies for reinventing the life cycle of plastics and textiles, announces that its project has been selected by the French State for funding of €30 million from the French State as part of the investment plan France 2030, and €12.5 million from the Grand-Est Region. The implementation of this funding is conditional to the European Commission's approval of the corresponding state aid scheme, followed by the conclusion of national aid agreements. As part of the national call for projects on "Plastics Recycling" operated by ADEM
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom